TSC2 and neoplasm: This may be due in part to the hostile tumor microenvironment, and to that end, creating CAR-T cells with a TSC2 SA mutation may help circumvent this limitation by improving effector function and long-term survival even in hypoxic and/or acidic microenvironments.